VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

IPOL
Vaccine Information
  • Product Name: Poliovirus Vaccine Inactivated (Monkey Kidney Cell)
  • Tradename: IPOL
  • Manufacturer: Sanofi Pasteur, SA
  • Vaccine Ontology ID: VO_0000054
  • CDC CVX code: 10
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1724)
  • Host Species for Licensed Use: Human
  • Antigen: Three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett).
  • Preparation: IPOL is a sterile inactivated vaccine suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Each of the three strains of poliovirus is individually grown in vero cells, a continuous line of monkey kidney cells cultivated on microcarriers. After clarification and filtration, viral suspensions are concentrated by ultrafiltration, and purified by liquid chromatography. After re-equilibration of the purified viral suspension, the monovalent viral suspensions are inactivated at +37°C for at least 12 days with 1:4000 formalin. Each dose (0.5 mL) of trivalent vaccine is formulated to contain 40 D antigen units of Type 1, 8 D antigen units.
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2°C to 8°C (35°F to 46°F). The vaccine must not be frozen (FDA: IPOL).
  • Contraindication: The vaccine should not be administered to persons with a history of hypersensitivity to any component of the vaccine (FDA: IPOL).
  • Description: All children should receive four doses of inactivated poliovirus vaccine (IPV) at ages 2, 4, 6 to 18 months and 4 to 6 years (FDA: IPOL).
Host Response

Human Response

  • Immune Response: In most clinical studies performed with this vaccine, the seroconversion rates have always been between 80% and 100% (FDA: IPOL).
  • Side Effects: The most common side effects reported include injection site reactions, fever, irritability and fatigue (FDA: IPOL).
References
FDA: IPOL: FDA: IPOL vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180053.htm]